COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00695851
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : March 30, 2009
Ambrilia Biopharma, Inc.
Information provided by:
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to find out whether giving a drug called PCK3145 can reduce the level of a protein in the blood called MMP-9 as well as to find out how long the drug will remain in your system over time. This drug has been tested previously in prostate cancer patients abroad and has been shown to be safe with minimal side effects. However, we do not know whether changes in MMP-9 levels correlate with tumor shrinkage or symptom improvement. We would also like to evaluate the potential pain relief (analgesic) effect of PCK3145 at 15mg/m² i.v. weekly for 12 weeks on patients with both symptomatic and asymptomatic castrate metastatic prostate cancer who are dependent on opioid analgesics. We would also like to monitor pain through a brief pain questionaire, and determine the impact on markers of bone turnover.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: PCK3145 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Randomized Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.
Study Start Date : March 2005
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: 1
15 mg/m2 weekly of PCK3145
Drug: PCK3145
i.v. bolus either 15 mg/m2 weekly of PCK3145.

Experimental: 2
7.5 mg/m2 twice per week of PCK3145
Drug: PCK3145
by i.v. bolus 7.5 mg/m2 twice per week of PCK3145

Primary Outcome Measures :
  1. To explore the PK profiles and their association with two dosing schedules of PCK3145 given iv bolus in patients with asymptomatic castrate metastatic prostate cancer. [ Time Frame: conclusion of the study ]

Secondary Outcome Measures :
  1. To explore the association of 2 dosing schedules of PCK3145 with MMP-9 levels in asymptomatic pts with castrate metastatic prostate cancer. The results of this analysis will be used to establish a dose on which to build a phase II randomized trial. [ Time Frame: conclusion of the study ]
  2. To assess the safety and toxicity of PCK3145 at a dose of 150mg/m² i.v. bolus given weekly for 16 weeks. [ Time Frame: conclusion of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have castrate metastatic prostate cancers are eligible based on the following criteria.
  • Patients with prostate cancer must have castrate metastatic disease (i.e. disease progression following castration or treatment with a gonadotropin releasing hormone analog. Patients with prostate cancer may have progressing metastatic disease on imaging studies (bone scan, CT scan or MRI) in addition to a rising PSA.
  • Biochemical progression will be defined as: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or two rising PSA values more than one month apart, where the percentage increase over the range of values is at least 25%.
  • Maintaining castrate status: Patients who have not undergone surgical orchiectomy should continue on medical therapies [i.e. gonadotropin releasing hormone analogs] to maintain castrate levels of serum testosterone. Patients who are receiving an anti-androgen as part of first line hormonal therapy must have shown progression of disease off the anti-androgen prior to enrollment.
  • Histologically confirmed diagnosis of prostate cancer per MSKCC review.
  • No limitations on the duration of or number of prior therapies.
  • Age ≥ 18 years
  • Karnofsky performance status ≥ 70% (ECOG ≤ 1.0).
  • Life expectancy of greater than 6 months.
  • Hematologic: WBC ≥ 3000K/μl.
  • Absolute neutrophil count ≥ 1500 K/μl
  • Platelet count ≥ 100,000 K/μl.
  • Hepatic: Total Bilirubin - within normal institutional limits
  • AST < 1.5 x ULN, ALT < 1.5 x ULN.
  • Renal: Creatinine < 2.0 or creatinine clearance > 55 mL/min
  • Coagulation: Prothrombin time - Less than or equal to the ULN (upper limit of normal) unless patient is taking anticoagulants
  • Patients must have recovered from the acute toxicities of any prior therapy, and not received chemotherapy, radiation therapy or other investigational anticancer therapeutic drugs for at least 4 weeks prior to entry.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Testosterone < 50 ng/dl
  • Patients may be symptomatic and must be dependent on opioid analgesics or nonsteroidal anti-inflammatory drugs

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from the adverse events due to agents administered more than 4 weeks earlier.
  • Patients may not be receiving any other investigational agents.
  • Patients with active brain metastases or epidural disease
  • Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • No current therapy with alternative/complementary drugs such as PC Plus, saw palmetto or Zyflamend.
  • No rectal bleeding except that seen following radiation proctitis or known history of hemorrhoids.
  • Non-prostate primary carcinoma except for non-melanoma skin cancer within previous 5 years.
  • No uncontrolled cardiac arrhythmias.
  • Patient taking steroids for cord compression or pain control are excluded. Patient on steroids for chronic conditions such as arthritis or asthma or on chronic hydrocortisone post ketoconazole will be permitted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00695851

Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Ambrilia Biopharma, Inc.
Layout table for investigator information
Principal Investigator: Susan Slovin, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: Susan Slovin, MD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00695851    
Other Study ID Numbers: 05-019
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: March 30, 2009
Last Verified: March 2009
Keywords provided by Memorial Sloan Kettering Cancer Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases